Evaluation of the early effects of the first-dose administration of the Sinovac vaccine on the retina, choroid, and optic disc using optical coherence tomography (OCT) and OCT-angiography

Article

Author: Arikan Yorgun, Mucella ; Saritas, Ozge ; Gurturk Icoz, Sule Gokcek ; Toklu, Yasin ; Yildiz Tasci, Yelda ; Icoz, Mehmet

AIMTo determine the effects of the first-dose administration of the Sinovac vaccine on the retina, choroid, and optic disc in healthy participants.METHODSThis prospective design study was conducted with 27 healthy healthcare workers who received the first dose of Sinovac vaccine and 25 healthy controls who were not vaccinated. In the vaccinated group, ophthalmological examinations and measurements were performed before vaccination and one week and one month after vaccination. Subfoveal, nasal, and temporal choroidal thicknesses (CTs), retinal nerve fiber layer (RNFL) thickness, and macular thickness (MT) were determined using spectral domain-optical coherence tomography at all visits. Superficial, deep, and peripapillary radial capillary plexus (superficial capillary plexus, deep capillary plexus (DCP), and radial peripapillary capillary, respectively), choriocapillaris vascular density, and foveal avascular zone parameters were measured on optical coherence tomography-angiography (OCT-A).RESULTSNo significant difference was detected between the two groups in terms of the parameters measured by OCT and OCT-A (p > 0.05 for all). The CT values measured in all quadrants were significantly higher at the first week after vaccination (p < 0.05 for all), and they returned to their pre-vaccination values at the first month post-vaccination measurement (p > 0.05 for all). Concerning the RNFL and MT values, there was no significant difference between the pre-vaccination and post-vaccination first-week measurements (p > 0.05 for all), but a statistically significant increase was detected in the post-vaccination first-month MT and RNFL measurements (p < 0.05 for all). Only the decreases in the foveal DCP and choriocapillaris vascular density values were significant at the first week after vaccination (p < 0.05 for all).CONCLUSIONThe early changes detected after vaccination in this study suggest the possibility that autoimmune, vascular, and inflammatory diseases may simultaneously emerge in the early post-vaccination period or may be triggered after vaccination, or that the vaccine may unmask these diseases.

01 Jan 2024·DIGITAL HEALTH

Understanding COVID-19 vaccine hesitancy of different regions in the post-epidemic era: A causality deep learning approach

Article

Author: Zhao, Chenxu ; Zhang, Chengzhi ; Liu, Yang

Objective This paper aims to understand vaccine hesitancy in the post-epidemic era by analyzing texts related to vaccine reviews and public attitudes toward three prominent vaccine brands: Sinovac, AstraZeneca, and Pfizer, and exploring the relationship of vaccine hesitancy with the prevalence of epidemics in different regions. Methods We collected 165629 Twitter user comments associated with the vaccine brands. The comments were labeled based on willingness and attitude toward vaccination. We utilize a causality deep learning model, the Bert multi-channel convolutional neural network (BertMCNN), to predict users’ willingness and attitude mutually. Results When applied to the provided dataset, the proposed BertMCNN model demonstrated superior performance to traditional machine learning algorithms and other deep learning models. It is worth noting that after March 2022, the public was more hesitant about the Sinovac vaccines. Conclusions This study reveals a connection between vaccine hesitancy and the prevalence of the epidemic in different regions. The analytical results obtained from this method can assist governmental health departments in making informed decisions regarding vaccination strategies.

20 Oct 2023·Medicine

Vaccine effectiveness against the B.1.617.2 in the intensive care unit

Article

Author: Koc, Ibrahim ; Unalli Ozmen, Sevda ; Deniz, Olgun

Severe acute respiratory syndrome-coronavirus 2 and its variants are still a concern for the World. The effectiveness of the BioNTech and Sinovac vaccines against the B.1.617.2 variant, particularly in the intensive care unit, has been unclear. This study aimed to investigate the vaccine effectiveness of BioNTech and Sinovac vaccines in reducing severe disease, intubation, and mortality rates in B.1.617.2 infected patients followed in the intensive care unit. The data of 208 unvaccinated and 234 vaccinated B.1.617.2 variants were retrospectively reviewed. Severe disease status, complaints, the percent oxygen saturation in the blood at the first admission, and other clinical information during follow-up were recorded. With the BioNTech and Sinovac vaccines being the most common in the region, mortality rate, severe disease, and intubation were more frequent in the unvaccinated group. As for survival rates, 58.5 (137) of the vaccinated and 35.1 % (73) of the unvaccinated survived. In the vaccinated group, 64.3 % (27) of vaccinated with 3 Sinovac, 80 % (16) of 2 Sinovac and 1 BioNTech, and 71.7 % of 2 BioNTech survived. Vaccination with 2 doses of BioNTech and 3 doses of Sinovac reduces mortality. Furthermore, 2 doses of Sinovac and 1 dose of BioNTech are more protective.

100 Deals associated with Rotavirus vaccine(Sinovac)

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Rotavirus vaccine(Sinovac)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation